Sichenzia Ross Ference LLP Represents Lexaria Bioscience Corp. in Close of $11 Million Underwritten Public Offering and NASDAQ Uplisting
Press Release – New York, NY – January 14, 2021 – Sichenzia Ross Ference LLP announced today that it represented Lexaria Bioscience Corp. (NASDAQ: “LEXX”), in a closing of an underwritten public offering of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit. Lexaria uses proprietary drug delivery technology, DehydraTECH™, improving the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. The gross proceeds from the offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses.
The offering was made pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC).
H.C. Wainwright & Co. acted as the sole book-running manager for the Offering.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Avital Perlman, and associate Jacob Tabman and law clerk Zachary Weiss.
- Sichenzia Ross Ference LLP Represents Laidlaw & Company (UK) Ltd. in $5.75 Million Public Offering and Nasdaq Uplisting of Silo Pharma, Inc. - October 1, 2022
- Mid-Level Corporate Associate - September 29, 2022
- Junior Level Corporate Associate - September 29, 2022